Trial reportLupus science & medicine2022
Urine proteomic insights from the belimumab in lupus nephritis trial.
Trial report in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Urinary proteins from stone formers promote calcium oxalate crystallization, growth and aggregation via oxidative modifications.Journal of advanced research · 2026Article
- Repeat kidney biopsy in pediatric lupus nephritis: an analysis of associated clinical-pathological features and outcomes.Frontiers in pediatrics · 2026Article
- Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.Rheumatology (Oxford, England) · 2025Article
- Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.JCI insight · 2024Article
- Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.JCI insight · 2024Article
- Investigating the value of urinary biomarkers in relation to lupus nephritis histopathology: present insights and future prospects.Frontiers in pharmacology · 2024Review
- Lupus Nephritis Risk Factors and Biomarkers: An Update.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveUrine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy.
methodsUrine samples from 54 Belimumab International Systemic Lupus Erythematosus-Lupus Nephritis trial participants (all with biopsy-proven LN) were collected at weeks 0, 24 and 52. At each time point, 1000 urinary proteins were quantified using antibody microarrays (Raybiotech Kiloplex), and their abundance was compared in responders (n=31) versus non-responders (n=22) and with belimumab treatment (n=28) versus standard of care therapy (n=26). Response was defined as proteinuria <500 mg/g
resultsBy week 52, CD163 was the urine protein with the most significant difference in abundance between complete responders (median 1.8 pg/mg
conclusionsReduction in urinary CD163 was strongly associated with complete renal response, confirming the results of multiple prior studies. Treatment with belimumab can be detected in the urine proteome, and further study is needed to determine whether modulation of CD23-mediated immune enhancement pathways might be implicated in LN treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.